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Abstract
Mitochondrial disease associated with the pathogenic
m.3243A>G variant is a common, clinically heterogeneous,
neurogenetic disorder. Using multiple linear regression and
linear mixed modelling, we evaluated which commonly assayed
tissue (blood N = 231, urine N = 235, skeletal muscle N = 77)
represents the m.3243A>G mutation load and mitochondrial
DNA (mtDNA) copy number most strongly associated with
disease burden and progression. m.3243A>G levels are corre-
lated in blood, muscle and urine (R2 = 0.61–0.73). Blood hetero-
plasmy declines by ~2.3%/year; we have extended previously
published methodology to adjust for age. In urine, males have
higher mtDNA copy number and ~20% higher m.3243A>G muta-
tion load; we present formulas to adjust for this. Blood is the
most highly correlated mutation measure for disease burden
and progression in m.3243A>G-harbouring individuals; increasing
age and heteroplasmy contribute (R2 = 0.27, P < 0.001). In
muscle, heteroplasmy, age and mtDNA copy number explain a
higher proportion of variability in disease burden (R2 = 0.40,
P < 0.001), although activity level and disease severity are likely
to affect copy number. Whilst our data indicate that age-
corrected blood m.3243A>G heteroplasmy is the most conve-
nient and reliable measure for routine clinical assessment, addi-
tional factors such as mtDNA copy number may also influence
disease severity.
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Introduction
The pathogenic mitochondrial DNA (mtDNA) m.3243A>G variant in
the MT-TL1 gene (encoding mt-tRNALeu(UUR)) is the most common
heteroplasmic mtDNA disease genotype (Goto et al, 1990; Elliott et al,
2008; Gorman et al, 2015, 2016). Disease burden and progression vary
greatly between individuals, and the associated clinical spectrum is
broad (Nesbitt et al, 2013). The cause of this heterogeneity is poorly
understood; consequently, disease burden and long-term prognosis are
very difficult to predict (Chinnery et al, 1997; Kaufmann et al, 2011;
Mancuso et al, 2014; Weiduschat et al, 2014; Fayssoil et al, 2017).
In individuals harbouring m.3243A>G, mutant and wild-type
mtDNA molecules coexist within the same cell, a situation termed
heteroplasmy. Tissue segregation patterns of m.3243A>G vary
widely; post-mitotic tissues such as muscle have higher levels of
mutant mtDNA, whilst levels in blood decrease significantly over
time (Sue et al, 1998; Rahman et al, 2001; Pyle et al, 2007; Raja-
simha et al, 2008; Mehrazin et al, 2009; de Laat et al, 2012).
Although patients with very severe disease tend to have a high
proportion of mutant mtDNA, the relationship between hetero-
plasmy level and clinical phenotype is not straightforward and such
intra-individual variation between tissues adds to the uncertainty
(Chinnery et al, 1997; Fayssoil et al, 2017).
We aimed to determine which putative prognostic factors are
most associated with m.3243A>G-related mitochondrial disease
burden and progression. To answer this question, we characterised
the levels of heteroplasmy and mtDNA copy number in three
commonly sampled tissues: blood, urine and skeletal muscle, in
242 m.3243A>G carriers (including 195 symptomatic patients) from
the MRC Mitochondrial Disease Patient Cohort UK. Using multiple
linear regression, we ascertained which m.3243A>G heteroplasmy
measure and mtDNA copy number were the most associated with
total disease burden, as determined by the Newcastle Mitochondrial
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Disease Adult Scale (NMDAS) (Schaefer et al, 2006). We used linear
mixed modelling to investigate disease progression.
Results
m.3243A>G heteroplasmy measures in all three tissues
are correlated
In the first instance, we sought to characterise the three measurements
of heteroplasmy; all are significantly correlated. The strongest relation-
ship is between blood and urine heteroplasmy levels (Fig 1A;
R2 = 0.73, P < 0.001; interaction with age included for a linear fit,
P < 0.001), followed by muscle and blood heteroplasmy levels (Fig 1B;
R2 = 0.64, P < 0.001, interaction with age included, P = 0.029).
Finally, urine and muscle levels are correlated (Fig 1C; R2 = 0.61,
P < 0.001, sex term included, see below). Urine levels are significantly
lower than muscle (slope = 0.75, 95% CI = 0.60–0.91, P < 0.001).
Blood and urine m.3243A>G heteroplasmy levels are negatively
correlated with age
The correlation between muscle and blood heteroplasmy (Fig 1A)
shows that younger individuals tend to have higher blood hetero-
plasmy levels, including age in the model increased R2 from 0.38 to
0.64 (P < 0.001), consistent with previous reports of a decline in
blood levels with age (Rahman et al, 2001; Pyle et al, 2007; Raja-
simha et al, 2008). We therefore examined the relationship of all
tissue heteroplasmy measures with age; both blood and urine
heteroplasmy levels show significant negative correlations, although
this is greater for blood than urine. Muscle heteroplasmy is not
correlated with age (Fig 1D–F).
Blood m.3243A>G heteroplasmy levels decline with time
To evaluate reports of an exponential decline in blood m.3243A>G
heteroplasmy level, we examined levels in all patients with multiple
measurements (Fig 2). Blood levels have declined in the majority of
patients observed for 4 years or more but this is not universal and
some individuals appear to reach a terminal nonzero plateau of
heteroplasmy; therefore, decline is not universally exponential. The
rate of heteroplasmy change in blood is not associated with disease
burden (P = 0.977), and individuals whose level increased or
remained stationary had a similar disease burden to those whose
levels decreased.
We regressed the rate of heteroplasmy change against initial
mutation level, estimating a continuous decline of 0.0185/year
(95% CI = 0.0421 to 0.0052), consistent with previous methodol-
ogy (Rajasimha et al, 2008). However, the model is a poor fit to our
data (R2 = 0.06, P = 0.120); this is improved if age at first measure-
ment is included (R2 = 0.42, P = 0.002), with older individuals
having a lower rate of decline.
Blood m.3243A>G heteroplasmy levels must be adjusted for age
To understand the decline in blood m.3243A>G levels across the
whole cohort, we modelled the decline in blood heteroplasmy using
adjusted urine heteroplasmy levels as an estimate of initial mutation
level (N = 204, see below) and validated our model using muscle
heteroplasmy levels. We propose the following formula for age
correction of blood heteroplasmy levels which represents a
compound decline of ~2.3% a year with an added age adjuster to
account for a rapid reduction in mutation load in early life
(Appendix Supplementary Method 2).
Age-adjusted blood level ¼ (Blood heteroplasmy)=0:977ðageþ12Þ
Mean age-adjusted blood heteroplasmy is significantly correlated
with mean muscle heteroplasmy (Fig 3A). This is an improvement
on unadjusted blood levels (R2 = 0.48 compared to 0.38), and the
two levels can be more easily compared (slope = 1.03, 95%
CI = 0.78–1.28). Adjusted levels are also correlated with urine
heteroplasmy (R2 = 0.60, P < 0.001, N = 224) and sex-adjusted
urine heteroplasmy (R2 = 0.64, P < 0.001, N = 224). There is a
relationship between age-adjusted blood heteroplasmy and age
(Fig 3B), but this is weaker and only seen in females.
Urine m.3243A>G heteroplasmy levels are dependent on sex
The correlation between urine and muscle heteroplasmy level shows
a clear effect of sex; males have, on average, 19.2% higher urine
heteroplasmy (Fig 1C; 95% CI = 12.6–25.8%). Including sex in the
model increases R2 from 0.43 to 0.61 (P < 0.001). Consistent with this,
a similar effect size is seen in Fig 1F; (male levels are 18.4% higher,
95% CI = 12.7–24.1%, P < 0.001). No relationship with sex is seen
for blood (P = 0.288) or muscle heteroplasmy levels (P = 0.245).
Urine m.3243A>G heteroplasmy levels must be adjusted for sex
Given the ~20% difference in m.3243A>G heteroplasmy levels
between males and females, we used the relationship between urine
and muscle levels to derive a method to adjust urine levels for sex
(Appendix Supplementary Method 1).
Summary of transformation:
Male adjusted urine level = logit1((logit (Urine heteroplasmy)/
0.791)0.625)
Female adjusted urine level = logit1((logit (Urine heteroplasmy)/
0.791)+0.608)
The adjusted levels are significantly correlated with muscle levels
(Fig 3C), an improvement on the correlation between uncorrected
urine and muscle levels (R2 = 0.55 compared to 0.43; sex not
included models). There is still a relationship with age, of a similar
magnitude to that seen in Fig 1F (Fig 3D).
For 22 individuals, m.3243A>G mutation load in muscle is diver-
gent from urine levels by > 20%; if adjusted urine levels are used,
this drops to 12, and if adjusted blood levels are also taken into
account, there are only five.
Urine m.3243A>G heteroplasmy measures have the
highest variability
We were interested in the intra-individual variability of measure-
ments. Urine heteroplasmy levels appear to have much greater vari-
ability than the other tissues; levels in a number of individuals
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Figure 1. Correlations between heteroplasmy measurements and their relationship with age.
A Urine and blood heteroplasmy correlation (N = 224, R2 = 0.73, P < 0.001; interaction with age included, P < 0.001)
B Muscle and blood heteroplasmy correlation (N = 74, R2 = 0.64, P < 0.001; interaction with age included, P = 0.029).
C Muscle and urine heteroplasmy correlation, showing different intercepts for males and females (N = 75, R2 = 0.61, P < 0.001).
D The relationship between age and muscle heteroplasmy levels (N = 77, R2 = 0.0, P = 0.491).
E The relationship between age and blood heteroplasmy levels (N = 231, R2 = 0.32, slope = 0.56, 95% CI = 0.67, 0.45, P < 0.001).
F The relationship between age and urine heteroplasmy levels (N = 235, R2 = 0.22, slope = 0.42, 95% CI = 0.62, 0.22, P < 0.001).
Data information: Points represent mean heteroplasmy level for each individual, and linear regression lines are shown with 95% confidence intervals.
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differ by 20–33%, and one individual shows a 55% change. In
contrast, the biggest change in blood is 15%.
To quantify the variability, we calculated the coefficient of varia-
tion (CV) for each individual with at least three repeated measure-
ments, allowing us to compare the variability across all tissues
(excluding muscle where N = 1). Age-adjusted blood shows the
smallest variability (N = 24, mean CV = 0.091, 95% CI = 0.051–
0.131), followed by unadjusted blood (N = 24, mean CV = 0.128,
95% CI = 0.084–0.171), although the difference is not significant
(P = 0.157). The highest variability is seen in urine (N = 39, mean
CV = 0.189, 95% CI = 0.148–0.230) and sex-adjusted urine (N = 39,
mean CV = 0.213, 95% CI = 0.166, 0.259), which are significantly
different from age-adjusted blood levels (both P < 0.001) and blood
levels (Purine = 0.034, Psex-adjusted urine = 0.015).
Total disease burden is most strongly associated with blood
heteroplasmy level
To determine which heteroplasmy measurement is most strongly
associated with total disease burden, we performed separate linear
regression using each heteroplasmy measure. All are significantly
associated, although the total variation explained by heteroplasmy,
age and sex is low (R2 range = 0.15–0.27; Table 1).
Age-adjusted blood (Fig 4A) and unadjusted blood hetero-
plasmy levels are more highly associated with total disease
burden than adjusted and unadjusted urine levels (Table 1). The
difference between using these two measures is small, failing to
reach significance (P = 0.173; Appendix Table S1); however, as
age was also included in the model, this is not surprising and
provides further validation of our method of adjustment. Sex-
adjusted urine level is the next most associated factor and better
than uncorrected urine levels (Table 1), although this difference is
not significant (P = 0.166; Appendix Table S1A). A composite
measure of adjusted blood and urine m.3243A>G levels explained
no more of the variance than using age-adjusted blood levels
alone. Interestingly, blood heteroplasmy is significantly more asso-
ciated with total disease burden than urine heteroplasmy
(P = 0.007) and this holds when both corrected measures are
used (P = 0.036; Appendix Table S1A).
In individuals with available muscle heteroplasmy data
(Table 1), using blood or urine heteroplasmy levels are just as good
as muscle (Appendix Table S1A).
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Figure 2. Decline of blood m.3243A>G heteroplasmy level.
Longitudinal blood heteroplasmy levels in individuals with multiple measurements (N = 96). Each point represents one heteroplasmy measurement; points joined by a line
representing individual patients. Patients observed over 4 years or more are highlighted in blue for those showing a decline (N = 21) or red for those who show no change or
an increase (N = 14).
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Disease progression rate is most strongly associated with
age-adjusted blood heteroplasmy level
We then asked whether heteroplasmy level is associated with
disease progression; we used a linear mixed model to examine the
role of heteroplasmy in the rate of NMDAS development. Disease
progression is most strongly associated with age-adjusted blood
levels, significantly more than urine (P = 0.010; Appendix
Table S1B) and sex-adjusted urine levels (P = 0.037). Although the
combination of adjusted blood and adjusted urine levels was
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Figure 3. Sex-adjusted urine and age-adjusted blood m.3243A>G heteroplasmy levels.
A Regression of age-adjusted blood heteroplasmy against muscle heteroplasmy (N = 74, R2 = 0.48, P < 0.001).
B Regression of age-adjusted blood heteroplasmy against age (N = 231, R2 = 0.06, P < 0.001) showing an interaction with sex (P = 0.022).
C Regression of sex-adjusted urine heteroplasmy against muscle heteroplasmy (N = 75, R2 = 0.55, P < 0.001).
D Regression of sex-adjusted urine heteroplasmy against age (N = 235, R2 = 0.07, slope = 0.50, 95% CI = 0.73, 0.27, P < 0.001).
Data information: Linear regression lines and 95% confidence intervals are shown.
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marginally more associated than adjusted blood levels alone, this
difference failed to reach significance (P = 0.624). Crucially, in
the cohort with available muscle heteroplasmy data, muscle
m.3243A>G levels were not more strongly associated with disease
progression than age-adjusted blood (P = 0.189), sex-adjusted urine
(P = 0.297), unadjusted urine levels (P = 0.320) or a combination of
adjusted blood and urine levels (P = 0.696).
Increasing age and the interaction between age and increasing
age-adjusted blood heteroplasmy level are significantly positively
associated with disease progression (P < 0.001); however, inter-
individual variation is extremely high; the standard deviation of the
variance due to individual is 2.35 (on NMDAS0.5 scale) compared to
0.04 for age. Although individuals with high heteroplasmy levels
tend to have a higher disease burden and rate of progression and
vice versa, there is a large spread in the data as well as considerable
overlap (Fig 4B).
Total mtDNA copy number is affected by m.3243A>G
heteroplasmy level (in blood) and sex (in urine)
As only 27% of the total disease burden can be explained by
m.3243A>G heteroplasmy level and age, we reasoned that the abso-
lute quantity of wild-type mtDNA could affect clinical phenotype.
We assessed mtDNA copy number in all three available tissues and
determined the relationship between mtDNA copy number, sex,
m.3243A>G heteroplasmy level and age. Standardised mtDNA copy
number was highest in muscle (median = 3523, IQR = 1708,
range = 678–10,610, N = 66) and lowest in blood (median = 144,
IQR = 81, range = 24–323, N = 197), whilst urine mtDNA copy
number showed the greatest range (median = 1181, IQR = 2870,
range = 77–24,730, N = 165).
Blood mtDNA copy number shows a weak positive correlation
with unadjusted (R2 = 0.03, P = 0.007) and age-adjusted (R2 = 0.02,
P = 0.016) m.3243A>G heteroplasmy level (N = 197). We observed
no association with sex (P = 0.088) or age (P = 0.163). Urine
mtDNA copy number is significantly higher in males (R2 =
0.12, P < 0.001, N = 176; medianmale = 3,733, IQRmale = 5,630,
medianfemale = 881, IQRfemale = 1,468), which is unsurprising given
the differences seen in m.3243A>G heteroplasmy level and is likely
to be due to differences in cellular composition. No association with
age (P = 0.628), unadjusted (P = 0.113) or sex-adjusted (P = 0.163)
urine heteroplasmy was observed. Muscle mtDNA copy number
shows a slight downward trend with age, although this does not
reach significance (R2 = 0.04, P = 0.060, N = 67). No association
with sex (P = 0.450) or muscle m.3243A>G heteroplasmy
(P = 0.725) was detected. We saw no correlation between copy
number in the three tissues studied (blood*-urine** P = 0.372,
N = 148; blood*-muscle P = 0.641, N = 59; urine**-muscle
P = 0.493, N = 52; *age-adjusted blood m.3243A>G heteroplasmy
or **sex included in model).
Low total mtDNA copy number in muscle is an indicator of
disease burden
To determine the effect of mtDNA copy number with disease
burden, we performed separate linear regression models for each
tissue, including age, m.3243A>G heteroplasmy level (assessed from
the same sample as copy number) and sex (only for urine) as
covariates. We found that higher skeletal muscle mtDNA copy
number is significantly associated with reduced total disease
burden in both single and multiple linear regression
(PmtDNA copy number < 0.001; N = 66; Fig 5). We estimate the effect
of an increase in mtDNA copy number of 100 is a decrease in
NMDAS0.5 by 0.055 (95% CI = 0.079–0.031), which is similar to the
effect of decreasing muscle m.3243A>G heteroplasmy by 1% (0.027,
95% CI = 0.008–0.046, P = 0.006). Indeed, mtDNA copy number,
muscle heteroplasmy and age account for 40% of the variance in
disease burden (P < 0.001); only 21% is explained when mtDNA
copy number is not included. No significant associations were found
for mtDNA copy number in either blood (Pblood = 0.551,
Page-adjusted blood = 0.586; N = 197) or urine (Purine = 0.144,
Psex-adjusted urine = 0.491; N = 165). The interaction between age and
muscle mtDNA copy number is associated with disease progression
(P = 0.0177, N = 63), but no association was seen for blood
(P = 0.2491, N = 197) or urine (P = 0.1726, N = 159).
Discussion
We have characterised m.3243A>G heteroplasmy levels and mtDNA
copy number in blood, urinary sediment and skeletal muscle,
describing previously unreported sexual divergences in urine
heteroplasmy and mtDNA copy number and confirming a longitudi-
nal and continuous decline in blood heteroplasmy level in the
majority of individuals. We have developed formulas to adjust urine
m.3243A>G heteroplasmy for sex and have extended previously
published methodology to adjust blood heteroplasmy levels for age,
accounting for a higher initial rate of decline.
Our data show that age, muscle heteroplasmy level and muscle
mtDNA copy number explain 40% of the variance in disease burden
in m.3243A>G-related disease. This is approaching the 49% vari-
ance in disease progression explained in single, large-scale mtDNA
deletion disease (Grady et al, 2014a). In contrast to previous
reports, we do not see significant associations with mtDNA
copy number in urine or blood and disease burden; however, our
Table 1. Comparisons of different m.3243A>G heteroplasmy measures
in association with total disease burden.
Heteroplasmy measure R2 P-value
Larger cohort (N = 210)
Blood 0.2744 < 0.001
Age-adjusted blood 0.2539 < 0.001
Urine 0.1809 < 0.001
Sex-adjusted urine 0.1989 < 0.001
Mean adjusted blood and urine 0.2461 < 0.001
Smaller cohort (N = 69)
Blood 0.1547 0.001
Age-adjusted blood 0.1809 < 0.001
Urine 0.1963 < 0.001
Sex-adjusted urine 0.2005 < 0.001
Skeletal muscle 0.2024 < 0.001
Mean adjusted blood and urine 0.1955 < 0.001
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Figure 4. Association of total disease burden and disease progression with age-adjusted blood heteroplasmy.
Points are coloured according to mean age-adjusted blood heteroplasmy level. Dashed lines and shading represent scores and 95% confidence intervals predicted using a
linear model (with the square root of NMDAS score as the dependent variable and age and age-adjusted blood heteroplasmy as independent variables) for individuals with
10% (blue), 50% (orange) and 90% (red) heteroplasmy levels.
A Association of total disease burden with age-adjusted blood heteroplasmy. Points represent mean NMDAS score per individual.
B Association of and disease progression with age-adjusted blood heteroplasmy. Each point represents one NMDAS assessment with points from each individual
connected by a solid line (N = 210).
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multi-variate models also include age and heteroplasmy, which may
account for this (Liu et al, 2006, 2013). This result suggests that
skeletal muscle is the most useful tissue to access and test in order
to understand m.3243A>G-related disease.
Where copy number assessment is not possible, we show that
muscle m.3243A>G heteroplasmy is not more highly associated with
disease burden or progression than blood or urine. Both adjusted
and unadjusted blood heteroplasmy levels are significantly more
associated than adjusted and unadjusted urine levels. This contra-
dicts previous studies (Mehrazin et al, 2009; Whittaker et al,
2009; de Laat et al, 2012) and may well reflect our larger sample
size, inclusion of age as a risk factor, and the significantly higher
within-individual variability that we observe in urine heteroplasmy
levels.
Together with age, blood and age-adjusted blood heteroplasmy
account for 25–27% of the variance in disease burden, consistent
with previous estimates (Whittaker et al, 2009; de Laat et al, 2012).
Individuals with high levels tend to have higher disease burden and
progression, but, even using muscle mtDNA heteroplasmy and copy
number, we observe meaningful inter-individual variation, high-
lighting the difficulties in providing accurate prognoses to patients
with m.3243A>G-related disease and implying that unidentified
factors, such as nuclear genetic variation, environmental influences
and epigenetics, affect clinical outcome (Picard & Hirano, 2016;
Pickett et al, 2018). Efforts to identify these, as well as the mecha-
nisms affecting mtDNA copy number and additional biomarkers for
disease severity, will be crucial to understanding m.3243A>G-
related mitochondrial disease.
The clear association with muscle mtDNA copy number and
disease burden may simply reflect that more severely affected indi-
viduals are likely to have lower activity levels, which may reduce
muscle mtDNA copy number (Apabhai et al, 2011; Cao et al, 2012).
Alternatively, some individuals may have a compensatory mecha-
nism of mitochondrial biogenesis triggered in the presence of
mutant mtDNA. MtDNA copy number has been shown to influence
the clinical outcome of patients carrying Leber hereditary optic
neuropathy mtDNA mutations; asymptomatic carriers have a higher
mtDNA copy number than both patients and healthy controls, with
fibroblasts from carriers also displaying the highest capacity for acti-
vating mitochondrial biogenesis (Giordano et al, 2014). Studies in
m.3243A>G cybrids have shown a positive correlation between
mtDNA copy number and O2 consumption, indicating that mtDNA
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Figure 5. Association of total disease burden with age, m.3243A>G heteroplasmy level and mtDNA copy number in skeletal muscle.
Lines represent scores predicted using a linear model (with the square root of NMDAS score as the dependent variable and age, skeletal muscle heteroplasmy and mtDNA
copy number as independent variables). Individuals with 10% (blue), 50% (orange) and 90% (red) heteroplasmy levels and low standardised mtDNA copy number (2,000
copies/nucleus; solid line), medium copy number (3,500 copies/nucleus; dashed line) and high copy number (5,000 copies/nucleus; dotted line) are represented.
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copy number may be a limiting factor in the cellular mitochondrial
respiratory phenotype within the context of this mutation (Bentlage
& Attardi, 1996). Compensatory mechanisms could well be tissue-
specific (we know that heteroplasmy plays a greater role for some
tissue-specific phenotypes than for others) and determined by envi-
ronmental or genetic factors, possibly accounting for some of the
phenotypic variability seen in this disease (Pickett et al, 2018). It
would therefore be fascinating to determine mtDNA copy number in
other commonly affected tissues, although the availability of post-
mortem nervous and cardiac tissue is likely to be restrictive. Our
confirmation of the role of mtDNA copy number in m.3243A>G-
related disease opens up the exciting possibility that components of
the mitochondrial biogenesis pathway could be targeted by drugs in
the treatment of this disease; indeed, change in skeletal muscle
mtDNA copy number should be considered as an outcome measure
for any clinical trial relating to m.3243A>G-related disease.
We characterised the decline in blood m.3243A>G heteroplasmy
levels over time, estimating a compound decline of 2.3%/year,
consistent with a previous estimate of 2% (Rajasimha et al, 2008).
However, our data show more variability, with 14 of 35 individuals
showing increasing or stationary blood heteroplasmy levels. There
is also clear evidence of either an initial rapid decline, a slowing of
decline with time, or both; evaluation of the relative contribution of
each requires further study.
In some individuals, blood levels of the m.3243A>G mutation
appear to drop to a nonzero and non-trivial proportion. Long-term
follow-up is necessary to fully characterise this inter-individual vari-
ation in selection against the m.3243A>G mutation. These individu-
als did not have a significantly different disease burden, but we had
limited power to detect an effect. Interestingly, four individuals (all
> 48 years of age) had detectable mutation loads in urine but not
blood, confirming that urine should also be checked for diagnosis if
m.3243A>G is suspected.
Our proposed method for calculating age-adjusted blood
m.3243A>G heteroplasmy produces levels better correlated with
muscle heteroplasmy. A negative correlation with age is still
present, although this is weaker and only in females. This is poten-
tially attributable to ascertainment bias, reflecting our active tracing
of m.3243A>G within pedigrees resulting in the recruitment of older,
mildly affected, females who are more likely to have lower hetero-
plasmy levels than their more severely affected offspring.
The biological cause of the drop in m.3243A>G levels in blood
remains unknown, but it is consistent with continuous selection
against haematopoietic stem cells with high mutation levels, a
theory supported by simulations although not by induced pluripo-
tent stem cell studies, which show marked bimodal segregation
towards homoplasmy (Rajasimha et al, 2008; Hamalainen et al,
2013; Kodaira et al, 2015). Along with the inter-individual variation
in the rate of decline, this suggests that any putative selection
process is not universal. Further studies to determine whether speci-
fic blood cell types are responsible for the reduction in level are
warranted and may offer insight into the mechanism of selection.
Our sex-adjusted urine m.3243A>G heteroplasmy levels are
better correlated with muscle levels than unadjusted levels, demon-
strating that they are likely to be a better overall surrogate for whole
organism heteroplasmy level. However, high intra-individual vari-
ability suggests that urinary sediment is not a reliable estimate of
heteroplasmy level if taken in isolation.
The observed variability and sexual divergence of m.3243A>G
heteroplasmy and mtDNA copy number in urinary sediment are
likely to be due to differences in cellular content. Urine contains
many different cell types, mostly epithelial in nature, and dif-
ferences in cellular composition arise depending on sex, age and
disease status (Benda et al, 2013). Other factors, such as time of
day, volume, concentration or infection, could also alter cellular
content and therefore influence measured heteroplasmy and copy
number levels. If urine is to be pursued for diagnostic testing of
m.34243A>G, variability in cellular content and the effect on hetero-
plasmy levels should be investigated. It is possible that this sexual
divergence also exists in other tissues and may explain some of the
sex-specific effects seen in mitochondrial disease (Giordano et al,
2014; Mancuso et al, 2014).
There are limitations to our study. We have not considered the
baseline level of disease found in the general population in our
model, although some features of m.3243A>G-related disease are
common (e.g. migraine). However, from a clinical care perspective,
overall disease burden is important, irrespective of aetiology. We
also recognise that the NMDAS may be weighted towards particular
phenotypes and so is not a perfect measure of disease burden;
however, it is clinically validated and widely used, and thus the
most appropriate tool currently available. Moreover, we have only
considered three tissues and our sample size for muscle is consider-
ably smaller than for urine and blood. Diagnostic facilities are
limited to relatively easily sampled tissues and are not always repre-
sentative of those commonly affected, which tend to be post-mitotic
with high-energy demand (e.g. skeletal and cardiac muscle and
central nervous tissue), but even in samples obtained from autopsy,
the relationships between tissue-specific symptoms and hetero-
plasmy levels are not clear (Betts et al, 2006; Maeda et al, 2016;
Picard & Hirano, 2016). Our study reflects the tissue availability in
many diagnostic settings, making our results clinically applicable.
Finally, our results represent mtDNA copy number and hetero-
plasmy in homogenate tissue; future work should determine these
levels in individual muscle fibres to determine whether muscle fibre
type has any influence. Taking account of this unknown and there-
fore uncontrolled variability may lead to a stronger correlation with
disease burden.
This study demonstrates that although a substantial amount of
variation in m.3243A>G-related disease burden remains to be
explained, the best correlates are skeletal muscle mtDNA copy
number, heteroplasmy and age, highlighting the importance of using
all three measurements to understand this condition. As skeletal
muscle mtDNA copy number is conceivably a marker for activity
level, which is affected by disease severity, it may have limited util-
ity in predicting likely disease burden. Blood m.3243A>G hetero-
plasmy levels are just as strongly associated with disease burden
and progression as muscle heteroplasmy levels; therefore, we
suggest that age-adjusted blood heteroplasmy is reliable and the
most convenient heteroplasmy measure to use routinely within the
clinical setting. Although urine may be a useful tissue for diagnosis
of m.3243A>G, our results suggest that urine heteroplasmy levels
should be adjusted for sex and are highly variable, and thus must
be interpreted with caution. We have developed a web-based tool
(http://www.newcastle-mitochondria.com/m-3243ag-heteroplasmy-
tool/) to calculate adjusted blood and urine m.3243A>G mutation
levels, supporting clinicians in their management of these patients.
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Future research should focus on identifying pathways responsible
for modulating mtDNA copy number in affected tissues, identifying
additional factors responsible for the extensive clinical variability
associated with this disease as well as collecting larger cohorts of
muscle samples in order to study the effect of muscle mtDNA copy
number on disease progression.
Materials and Methods
Study population
These studies were undertaken using data from 242 adult
m.3243A>G carriers (147 females, Appendix Table S2) recruited into
the MRC Mitochondrial Disease Patient Cohort UK between 2005
and 2017; all individuals were investigated by the NHS Highly
Specialised Service for Rare Mitochondrial Disorders of Adults and
Children in Newcastle upon Tyne. Patient follow-up was carried out
(median interval = 1.1 years, IQR = 0.77) using the Newcastle Mito-
chondrial Disease Adult Scale (NMDAS), a validated scale to evalu-
ate multi-system involvement and disease burden in adult
mitochondrial disease (Schaefer et al, 2006). The cohort includes
195 symptomatic patients (NMDAS score ≥ 5), 30 asymptomatic
carriers (NMDAS < 5) and 17 with incomplete NMDAS data.
The NMDAS assessment comprises 29 questions rated on a scale
of 0–5; we calculated the sum of these (excluding the score for respi-
ratory function, which is challenging to record accurately). NMDAS
assessments with fewer than 25 of 29 responses were excluded. For
those included, the total NMDAS score was divided by the number
of questions answered and multiplied by 29 to derive a scaled
NMDAS score.
Of the 242 individuals, 231 had at least one m.3243A>G hetero-
plasmy measurement in blood, 235 in urine and 77 in skeletal
muscle. We excluded post-renal transplant urine heteroplasmy
measurements from two patients after observing a large post-trans-
plant reduction in mean urine heteroplasmy level (35 to 3%,
N = 1).
For patients with multiple NMDAS assessments (N = 166), the
median follow-up time was 3.75 years (IQR = 4.95, max = 11.9)
with a median of three assessments per patient (IQR = 4,
max = 16). The median age at last assessment was 43.7 years
(IQR = 21.9, range = 19.7–79.9). The median maximum scaled
NMDAS score in patients with all three heteroplasmy measurements
available was 21.8 (IQR = 24.8, range = 1.0–103.7, N = 69) and in
patients who only had urine and blood heteroplasmy measurements
available was 16.6 (IQR = 23.8, range = 0–84.9, N = 141).
Informed consent was obtained from all subjects and that experi-
ments conformed to the principles set out in the WMA Declaration
of Helsinki and the Department of Health and Human Services
Belmont Report.
Heteroplasmy measurements
Total DNA was extracted from skeletal muscle (tibialis anterior
or vastus lateralis), urinary sediment, and blood by standard
procedures. Pyrosequencing on the Pyromark Q24 platform
permitted quantification of m.3243G>A heteroplasmy levels, as
previously described and validated (de Laat et al, 2016), with
mutation-specific pyrosequencing primers according to GenBank
Accession number NC_012920.1: 50biotinylated forward: m.3143-
3163; reverse: m.3331-3353; and reverse pyrosequencing primer:
m.3244-3258 (IDT, Coralville, USA). The allele quantification
application of Pyromark’s proprietary Q24 software was used to
calculate heteroplasmy levels (level of test sensitivity > 3%
mutant mtDNA).
mtDNA copy number assessment
mtDNA copy number was determined by real-time PCR using single-
plex Taqman assays targeting mitochondrial MT-ND1 and nuclear
B2M as previously described and validated (Grady et al, 2014b).
Primers and probes were as follows: B2M (GenBank accession
number: NG_012920) forward: n.8969-8990; B2M reverse: n.9064-
9037; and 50 6-FAM labelled B2M probe n.9006-9032; MT-ND1
(GenBank accession number NC_012920.1) forward: m.3485-3504;
MT-ND1 reverse: m.3553-3532; and 50 VIC-labelled MT-ND1 probe
m.3506-3529. Probes contained a non-fluorescent quencher and 30
MGB moiety. DNA was serially diluted to ~10 ng/ll for B2M and
~0.1 ng/ll for ND1; 5 ll DNA was added to each 15 ll reaction.
Each 96-well plate contained a standard curve derived from six
tenfold serial dilutions of a plasmid containing both B2M and ND1
targets. R2 values were > 0.999 and gradients fell between 3.3 and
3.6 for all standard curves. Each reaction was performed in tripli-
cate; mean threshold cycle (Ct) and standard curves were used to
determine the mtDNA copy number per nucleus for each sample.
Within sample outliers and samples with Ct standard deviation Ct
> 0.3 or mean Ct > 33 were excluded from the analysis. A control
DNA sample included on each plate (coefficient of variation of copy
number from 22 plates = 16.8%) was used to standardise mtDNA
copy number to control for inter-plate variation using the following
formula: standardised copy number = (copy number/on-plate
control copy number) x mean control copy number.
Statistical analysis
Linear regression
All statistical analyses were performed using the R statistical pack-
age (R Core Team, 2016). For initial investigations, the mean hetero-
plasmy level and age for each heteroplasmy subtype were utilised,
yielding a single independent data point per individual. To quantify
the relationships between different heteroplasmy measurements and
heteroplasmy with age and time, linear regression was performed.
Where appropriate, sex and age and interaction terms were tested
for inclusion in models using the analysis of variance test (threshold
P < 0.05). Model assumptions were checked by visual inspection of
plots of residuals against fitted values, QQ and leverage (threshold;
Cook’s distance of < 1). We report adjusted R2 values, P values
(3dp) and, where appropriate, slopes and 95% confidence intervals
(CI). We report unadjusted P values for reasons well documented in
the literature and, particularly as we are testing a priori hypotheses
with variables that are not all independent, this would be too
conservative (Perneger, 1998).
Quantifying variability
In order to quantify the variability in heteroplasmy measurements,
we calculated the standard deviation of measurements for each
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individual with at least three repeated measurements, adjusted for
small N to remove estimator bias (Holtzman, 1950). We derived
coefficients of variation (CV) by dividing by the population hetero-
plasmy mean, expressing variation as a proportion of the mean,
therefore, allowing for the different population means between
tissue heteroplasmy levels (Brown, 1998). We compared the mean
and standard deviation of the CVs across the heteroplasmy measure-
ments using two-tailed Wilcoxon rank sum tests with continuity
correction.
Disease burden
For all analyses using NMDAS score, the square root was taken to
ensure normality of the residuals. For total disease burden, a single
independent point for each subject was determined by taking the
maximum scaled NMDAS score and the earliest age at which this
was reached. Separate linear regression using each of the different
m.3243A>G heteroplasmy measures was performed, including age
and heteroplasmy as predictors of square root scaled NMDAS score.
To compare models, the difference between R2 values was
calculated as a measure of improvement in the model. Significance
(P values representing the probability of the second model being
better than the first) and 95% CIs of the difference in R2 values were
determined by bootstrapping (1,000 replicates).
Disease progression
To quantify the association between m.3243A>G heteroplasmy,
age and progression of disease burden, we used nlme (Pinheiro
et al, 2016) to perform a linear mixed effects analysis of the rela-
tionship between heteroplasmy level, age and NMDAS scaled
score. As a fixed effect, we entered age into the model. As random
effects, we had by-subject random slopes for the effect of age and
the interaction between age and heteroplasmy level (heteroplasmy
on its own was dropped from the model as P > 0.05) and no inter-
cept (making the assumption that individuals were asymptomatic
at birth). Two-sided P values were obtained from the t-distribution
reported in nlme. To assess which m.3243A>G heteroplasmy
measure was most highly associated with disease burden, we
selected the model with the lowest Akaike information criterion
(AIC). Bootstrapping with 1,000 replicates determined the mean
difference between AIC values, 95% CIs and significance. Reported
P values represent the number of samples with an AIC difference
less than zero (representing the first model being a better fit than
the second model).
Expanded View for this article is available online.
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The paper explained
Problem
The pathogenic m.3243A>G mitochondrial DNA variant, responsible for
a highly heterogeneous neurogenic disorder, is thought to be present
in up to one in 400 individuals. It is not only the most common
mutation in our mitochondrial disease patient cohort but also the
most problematic; giving accurate advice to patients regarding likely
disease burden and progression remains incredibly challenging, nearly
30 years since this heteroplasmic pathogenic mtDNA variant was first
described. A high mutation load is thought to be associated with
more severe disease, but variation in heteroplasmy levels in
commonly sampled tissues and a decline in levels in blood with age
adds to the uncertainty.
Results
We have characterised m.3243A>G mutation load and mtDNA copy
number in three commonly sampled tissues: blood, urinary sediment
and skeletal muscle. m.3243A>G mutation load in urine has the high-
est variability and is about 20% lower in females compared to males;
we present a method to adjust levels for this effect. We also extend
previous methodology to adjust blood heteroplasmy levels for the age
of the individual, accounting for non-uniform decline throughout a
subject’s lifetime. Blood m.3243A>G heteroplasmy levels are more
strongly associated than urine levels; 27% of the variance in disease
burden can be attributed to m.3243A>G heteroplasmy and age. Skele-
tal muscle mtDNA copy number, heteroplasmy and age together
explain 40% although mtDNA copy number in muscle is likely to be
affected by activity level and therefore disease severity.
Impact
Our evidence suggests that clinicians should use age-adjusted blood
m.3243A>G mutation load, along with patient age, as an indicator of
likely disease burden. If m.3243A>G mutation load data for urine are
available, these must be adjusted for the divergence between male
and female levels and interpreted with caution due to high variability.
If available, skeletal muscle samples could also be used to assay
mtDNA copy number, providing valuable information about mitochon-
drial biogenesis in m.3243A>G-related disease. As the proportion of
explained variance remains low, further work to identify additional
factors associated with disease burden and progression in patients
harbouring the pathogenic m.3243A>G variant is warranted.
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